Iomai gets grant to work on anthrax patch

Published



The patch: not just for nicotine addicts anymore.

Gaithersburg-based biotech company Iomai Corp. announced Tuesday it was receiving a small grant, just under $1 million, from the U.S. Army Medical Research and Material Command for work on a patch-based anthrax vaccine.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.